Oncotarget

Vol 2, No 5

May 2011

View Archive »

Order a Reprint

About The Cover

Paclitaxel inhibition of cell migration. A mixed culture of wild-type CHO cells and HAβ3-5 cells was scratched to make a wound and the cells were allowed to migrate for 24 h in the absence or presence of 10 nM paclitaxel. The cells were then stained for α-tubulin (red), HAβ3-tubulin (green), and DNA (blue). See Ganguly et al.

Table of Contents

Editorial Comments

Mycoplasmas and Human prostate cancer: An exciting but cautionary note

Mycoplasmas and Human prostate cancer: An exciting but cautionary note

https://doi.org/10.18632/oncotarget.282

Shyh-Ching Lo,  and Shien Tsai
352-355
Abstract  |  PDF  |  HTML  |  Order a Reprint

Proteotoxic stress targeted therapy (PSTT)

Proteotoxic stress targeted therapy (PSTT)

https://doi.org/10.18632/oncotarget.284

Michael Y. Sherman
356-357
Abstract  |  PDF  |  HTML  |  Order a Reprint

Brief Reports

Xenotropic murine leukemia virus-related virus (XMRV) in prostate cancer cells likely represents a laboratory artifact

Xenotropic murine leukemia virus-related virus (XMRV) in prostate cancer cells likely represents a laboratory artifact

https://doi.org/10.18632/oncotarget.287

Jiawen Yang, Partho Battacharya, Ruchi Singhal,  and Eugene S. Kandel
358-362
Abstract  |  PDF  |  HTML  |  Order a Reprint

Research Papers

Netrin-1 overexpression is predictive of ovarian malignancies

Netrin-1 overexpression is predictive of ovarian malignancies

https://doi.org/10.18632/oncotarget.258

Anastasios D. Papanastasiou, Georgios Pampalakis, Dionyssios Katsaros,  and Georgia Sotiropoulou
363-367
Abstract  |  PDF  |  HTML  |  Order a Reprint

Class III β-Tubulin Counteracts the Ability of Paclitaxel to Inhibit Cell Migration

Class III β-Tubulin Counteracts the Ability of Paclitaxel to Inhibit Cell Migration

https://doi.org/10.18632/oncotarget.250

Anutosh Ganguly, Hailing Yang,  and Fernando Cabral
368-377
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

Network Modeling of MDM2 Inhibitor-Oxaliplatin Combination Reveals Biological Synergy in wt-p53 solid tumors

Network Modeling of MDM2 Inhibitor-Oxaliplatin Combination Reveals Biological Synergy in wt-p53 solid tumors

https://doi.org/10.18632/oncotarget.269

Asfar S. Azmi, Sanjeev Banerjee, Shadan Ali, Zhiwei Wang, Bin Bao, Frances WJ Beck, Anthony F. Shields, Philip Philip, Fazlul H. Sarkar,  and Ramzi M. Mohammad
378-392
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis

No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis

https://doi.org/10.18632/oncotarget.278

Katharina Bluemlein, Nana-Maria Grüning, René G. Feichtinger, Hans Lehrach, Barbara Kofler,  and Markus Ralser
393-400
Abstract  |  PDF  |  HTML  |  Order a Reprint

Research Perspectives

YB-1 drives preneoplastic progression: Insight into opportunities for cancer prevention

YB-1 drives preneoplastic progression: Insight into opportunities for cancer prevention

https://doi.org/10.18632/oncotarget.276

Alastair H. Davies,  and Sandra E. Dunn
401-406
Abstract  |  PDF  |  HTML  |  Order a Reprint

Casein kinase 2 phosphorylation of Hsp90 threonine 22 modulates chaperone function and drug sensitivity

Casein kinase 2 phosphorylation of Hsp90 threonine 22 modulates chaperone function and drug sensitivity

https://doi.org/10.18632/oncotarget.272

Mehdi Mollapour, Shinji Tsutsumi, Yeong Sang Kim, Jane Trepel,  and Len Neckers
407-417
Abstract  |  PDF  |  HTML  |  Order a Reprint

Novel insights into the synergistic interaction of Bortezomib and TRAIL: tBid provides the link

Novel insights into the synergistic interaction of Bortezomib and TRAIL: tBid provides the link

https://doi.org/10.18632/oncotarget.277

Simone Fulda
418-421
Abstract  |  PDF  |  HTML  |  Order a Reprint

c-JUN prevents methylation of p16INK4a (and Cdk6): the villain turned bodyguard

c-JUN prevents methylation of p16INK4a (and Cdk6): the villain turned bodyguard

https://doi.org/10.18632/oncotarget.279

Karoline Kollmann, Gerwin Heller,  and Veronika Sexl
422-427
Abstract  |  PDF  |  HTML  |  Order a Reprint


Copyright © 2017 Impact Journals
Impact Journals is a registered trademark of Impact Journals, LLC